The solubility of the stable FIII polymorph of the pharmaceutical compound carbamazepine was measured by determining its solubility gravimetrically in ethanol and methanol. Where the metastable FI polymorph was suspended in a solution of ethanol, the stable FIII polymorph nucleated immediately initiating a solution mediated transformation from FI to FIII. This meant that the FI polymorph was not in thermodynamic equilibrium with the solution as FI was continually dissolving while FIII was growing. We show that the solubility of FI can be accurately measured by in situ microscopy using an adaption of the bracketing method and the results show that the solubility is close to but higher than the maximum solution concentration reached during the solution mediated transformation from FI to FIII carbamazepine in both 2 solvents. The technique demonstrates a relatively simple and robust method for determining the solubility of a metastable crystalline phase which transforms quickly in solution.
INTRODUCTION
The solubility of a crystalline compound provides vital thermodynamic information required to design crystallization processes, engineer the crystal size distribution and understand the phases which nucleate in the case of multiple-phase systems. Polymorphs are solid phases of the same compound but with different crystal structures. These different crystal structures exist due to the different molecular arrangements of the molecules giving rise to differences in free energy and thus solubility. 1 A particular polymorph may have more favourable processing or performance characteristics over another. For example, Form II of ranitidine hydrochloride has improved filtration properties compared to Form I 2 and the orthorhombic polymorph of paracetamol is more suitable for compression and tableting than the monoclinic polymorph. 3 Whether selection of a metastable or the stable polymorph is desired for a crystallization process, knowledge of the solubility of both phases is critical.
A thermodynamically stable polymorph will not undergo a transformation and so its solubility is readily measured by allowing the crystalline phase to reach equilibrium with the solution, provided solvates are not formed in that particular solvent. However, a metastable crystalline phase in solution can often quickly transform to a more stable phase 4 via the process of solution mediated transformation, 5 a process where the metastable solid phase dissolves and the stable phase nucleates and grows independently from solution. The maximum achievable solution concentration during such a process is governed by both dissolution of the metastable phase and growth of the stable phase and this can establish a kinetic steady-state for the solution concentration. Under such conditions, with the metastable phase dissolving the stable phase growing, the metastable phase is not strictly in equilibrium with the solution and so a strict measure of the thermodynamic equilibrium concentration for the metastable phase is not possible. This kinetic steady-state has been re iously referred to as "a arent" solubility, because it represents the maximum in concentration reached by dissolution of the metastable phase. 6 The triclinic polymorph (FI) of the pharmaceutical compound carbamazepine (CBZ) is an example a metastable phase known to undergo such as solution mediated transformation. The FI polymorph quickly transforms to the stable P-monoclinic polymorph (FIII) upon addition to a solution of methanol saturated with respect to FIII. 7 In practice, measuring the solubility of a crystalline phase (solute) and its variation with temperature is typically approached in one of two ways. The system, e.g. solute and solvent, is allowed to reach equilibrium at a specific temperature and the concentration of the solute in the system is measured via techniques such as gravimetric analysis, 8 titration, 9 UV-vis spectroscopy, 10 HPLC 11 or solution density. 12 Alternatively the system is examined for the point of equilibrium as a function of temperature, at a specific concentration of components. The latter can be achieved with techniques such as the synthetic method, 13 using differential scanning calorimetry (DSC), 14 in situ infra-red spectroscopy 15 and microscopic methods. 16 In this paper, we present both of these approaches to measuring polymorph solubility. The gravimetric method was used to measure the solubility of the stable FIII CBZ polymorph. Due to the transformation of the FI polymorph to FIII in bulk experiments where FIII nucleated immediately with no induction time, we developed an adaption of the bracketing method 17 to measure the FI solubility using in situ optical microscopy.
EXPERIMENTAL SECTION Polymorph Preparation
Pharmaceutical grade carbamazepine (FIII) having a purity >98% was obtained from POLPHARMA S.A. (Starogard Gdański, Poland) and stored in the resence of silica gel (0% humidity). ACS reagent grade ethanol (EtOH) and methanol (MeOH) were used having a purity of 99.9% and ≥99.8 %, res ecti ely.
The FIII polymorph of CBZ was prepared by crystallization from ethanol using an automatic lab reactor where 36.9 g of pharmaceutical grade CBZ was dissolved in 393 g of ethanol at 78 °C. The solution was quickly cooled to 10 °C and aged for 24hrs. The solids were harvested using vacuum filtration and dried at 25 °C in a vacuum oven for approximately 40 mins and analysed by powder X-ray diffraction (PXRD) using a Panalytical X'Pert MPD PRO X-ray diffractometer. To prepare the FI CBZ polymorph, 3 g of FIII CBZ powder was placed on a clock glass. This was then placed on aluminium foil and covered by a glass petri dish before heating the CBZ powder in the oven at 170°C for 2.5 hrs under full vacuum. Thereafter, the pressure was adjusted to ambient and the powder was held for 15-20 mins. The powder was allowed to cool slowly to 100°C before removing from the oven and placing in a dessicator to reach room temperature. The bulk powder was analysed by PXRD. Needle-like particles were grown on the underside of the pertri dish due to sublimation. Single crystal X-ray diffraction (Oxford Diffraction Xcalibur system at ambient temperature) was used to identify the needle-like particles as the triclinic FI polymorph of carbamazepine. These were used for measuring the 5 solubility of FI by in situ optical microscopy. Each polymorph was separately imaged using a Zeiss axioscope A1m imager optical microscope.
Solubility measurements
The solubility of FIII in ethanol and methanol respectively was measured by adding excess FIII in contact with approx. 30 mL of solvent in a sealed test tube. Isothermal temperature control at each temperature was achieved using a thermostatic water bath (Grant GR150, S38 stainless steel, ±0.02 °C) in which the test tube was placed. Agitation in the test tube was provided with the use of a PTFE-coated magnetic stirrer bar. After 24 hrs at each temperature the stirring was switched off to allow the suspended solid to settle for 30mins. A solution sample of ~2 mL was carefully filtered (0.22 μm filter) into a reweighed ial and then weighed to determine the solution mass. After drying in the fumehood, the vials were transferred to an air oven (Binder series VD 53) at 50°C for 24 hrs. The last hour drying was carried out under vacuum at ~300mBar. This was to assure perfect dryness and to remove any potential water of hydration, as CBZ is known to form a dihydrate structure. 18 The remaining solute was weighed and the concentration was expressed as g of solute/g of solvent. Each solution sample was performed in triplicate. Weighing was carried out using a Mettler-Toledo AX054 laboratory balance with a readability of 0.1 mg. A solid sample was also vacuum filtered at the time of 
Microscopic Solubility Measurements
In order to measure the solubility of FI, we used an experimental set-up previously developed (ANACRISMAT) to investigate solution mediated phase transitions of an pharmaceutical compound and a protein. 6, 19 The set-up consists of a Nikon Diaphot inverted optical microscope used in conjunction with an adapted Peltier temperature control unit (±0.1 °C) designed to fit an optical holding cell. The optical holding cell was used to hold and seal a quiescent solution sample in which a single crystal of FI could be observed. An adaption of the bracketing method was used to perform the solubility measurements. 19 The bracketing method typically involves producing a solution of known concentration/composition and varying the temperature until the point of equilibrium is reached where crystals neither dissolve nor grow. 17 The solubility of FIII in ethanol and methanol are presented in Table 1 . For each solubility measurement, PXRD identified FIII as the only phase present in solution at the time of sampling.
The temperature was also observed to be accurate to within ±0.05 °C during solution sampling.
The solubility of FIII increases with temperature in both solvents and agrees well with the solubility data of Liu et al. measured for FIII in these solvents using the synthetic method. peaks of FIII, respectively. These peaks are distinct from a very minor (02-3) FI peak at 15.6 13 °2θ. F was detected in the excess solid after 10 mins ( Figure 5B ). The presence of FIII was also detectable after 10 mins at 10 and 30 °C when FI was suspended in excess in ethanol. The solvent methanol was chosen for the in situ microscopy experiments to enable the solubility of FI to be determined for a number of temperatures in a relatively efficient timeframe.
CBZ has a higher solubility in methanol relative to ethanol and the processes of growth and dissolution (necessary to observe for concentrations outside of the FI equilibrium concentration) are generally faster in the solvent with higher solubility. 21 Using in situ optical microscopy, the solubility of FI in methanol was measured by continuously observing a single crystal of FI in a solution of known concentration and at a constant temperature, where the variation in temperature was observed to be within ±0.1 °C. In conditions where the solution concentration was undersaturated with respect to FI, dissolution was evident and when supersaturated with respect to FI, growth was evident, before the nucleation of FIII. Some in situ microscopy images illustrating these phenomena are presented in Figure 6 . The solubility of FI measured by in situ microscopy using the adapted bracketing method is summarised in Table 2 . a -the solubility data for FIII at 22 °C in methanol was calculated by interpolation of the data in Table 1 The data in Table 2 show that the FI solubility increases with temperature and is greater than that of FIII. The chemical potential difference between each polymorph, approximated by calculating RTlnS (shown in Table 2 ), decreases with increasing temperature. This indicates the existence of a temperature at which the chemical potential of FI will equal that of FIII, known as the thermodynamic transition temperature (T t ) and above this temperature the thermodynamic stability order of the polymorphs changes, where FI will be the more stable polymorph. Using a straight line approximation, a an't Hoff plot of the solubility data of FI and FIII in methanol was extrapolated to determine this temperature. A transition temperature of 77 °C was calculated from the an't Hoff lot in Figure 7 . This tem erature lies below the melt tem erature of all polymorphs of CBZ (189-191 °C) 1 
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The solubility of FI at 10 °C is 0.0940 (±0.0048) g CBZ / g MeOH as measured in Table 2 .
This value is close to but significantly higher than the previously reported solubility value of 0.0874 (±0.0001) g CBZ / g EtOH measured gravimetrically where a kinetic steady-state was established as FIII nucleated with no detectable induction time and FI dissolved while FIII grew. 7 To investigate if this previously reported solubility value, a solution concentration of 0.0874 g CBZ / g MeOH was prepared and the method with in situ microscopy, previously described, was used to examine for growth, dissolution or no change in particle size of FI at 10 °C in the prepared solution. In Figure 8 The FI and FIII polymorph solubility ratio, measured in methanol (Table 2) , were used to calculate the solubility of FI in ethanol. ssuming the acti ity coefficient, γ, is inde endent of small changes in concentration, particularly for a compound with relatively low solubility, the approximation was made that the polymorph solubility ratio was independent of the solvent. 27 γ 20 was considered constant for the case of a relatively small change in solubility in going from methanol to ethanol (approximately 3 times for FIII solubility data - Table 1 ). The solubility of FI in ethanol was calculated using the measured solubility of FIII in ethanol, from Table 1 , and the solubility ratio in methanol (in mole fraction). The calculation was made by converting the g CBZ / g MeOH data for FI and FIII solubility to mole fraction of CBZ and using the solubility ratio to calculate the solubility of FI in ethanol, first in mole fraction then in g CBZ / g EtOH.
The calculated solubility of FI and the measured solubility of FIII in ethanol is presented in It is well understood that the presence of a plateau in concentration for the transformation profiles in Figure 4 show that the dissolution of FI is faster than the growth of FIII. 5 This would explain why the maximum solution concentration reached during the transformation is close to the solubility of FI. However, for a strict measure of the FI solubility, FI must be in equilibrium with the solution and this requires balance between dissolution and growth rates occurring at the surfaces of the FI crystal. The nucleation and growth of FIII on the surfaces of FI may potentially disrupt this balance which may obstruct the solution from reaching thermodynamic equilibrium with FI.
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The absence of the immediate nucleation of FIII for the in situ microscopy measurements is a distinct difference compared to the bulk experiments which attempted to measure the FI solubility gravimetrically. It is this difference between the methods that facilitates the accurate measurement of FI solubility. A more precise measurements of FI solubility may be possible by this method if a larger magnification was used to measure the growth or dissolution of a specific crystal face. 28 However, due to the crystallization of FIII at concentrations close to the solubility of FI, this approach may prevent the ability to observe FIII nucleation and growth if it does not occur on the specific face being observed during the experiments and thus such an approach could potentially introduce errors into the FI solubility measurements. Our approach, using lower magnifications, presents a robust method for observing FI dissolution, growth or no change in crystal particle size while simultaneously checking for the crystallization of the more stable FIII polymorph. This has enabled the measurement of the solubility of the FI polymorph of CBZ which otherwise quickly transforms under bulk experimental conditions.
CONCLUSION
The solubility of FIII CBZ was measured gravimetrically in ethanol and methanol. The 
